

---

## Contents

<i>Preface</i> . . . . .	<i>v</i>
<i>Contributors</i> . . . . .	<i>ix</i>
1 On Setting Up and Assessing Docking Simulations for Virtual Screening. . . . . <i>Jacek Biesiada, Aleksey Porollo, and Jaroslaw Meller</i>	1
2 Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling . . . . . <i>Jufang Shan and Jie J. Zheng</i>	17
3 Rational Design of Rho GTPase-Targeting Inhibitors . . . . . <i>Xun Shang and Yi Zheng</i>	29
4 Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies. . . . . <i>Wenyong Tong, Tara Sprules, Kalle Gehring, and H. Uri Saragovi</i>	39
5 A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors . . . . . <i>Sheng Zhang, Lan Chen, David S. Lawrence, and Zhong-Yin Zhang</i>	53
6 Identification of Allosteric Inhibitors of p21-Activated Kinase . . . . . <i>Julien Viaud and Jeffrey R. Peterson</i>	67
7 Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors. . . . . <i>Anne Blangy and Philippe Fort</i>	81
8 Random Mutagenesis of Peptide Aptamers as an Optimization Strategy for Inhibitor Screening . . . . . <i>Nathalie Bouquier, Sylvie Fromont, Anne Debant, and Susanne Schmidt</i>	97
9 A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor. . . . . <i>Charles S. Craik and Tina Shahian</i>	119
10 Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1 . . . . . <i>Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi</i>	133
11 Affinity Purification of Protein Kinases that Adopt a Specific Inactive Conformation . . . . . <i>Pratistha Ranjitkar and Dustin J. Maly</i>	143
12 Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein Kinases . . . . . <i>Sanjay B. Hari, Pratistha Ranjitkar, and Dustin J. Maly</i>	153
13 Purification and Specific Assays for Measuring APE-1 Endonuclease Activity . . . . . <i>Adrian Esqueda, Mohammed Z. Mohammed, Srinivasan Madhusudan, and Nouri Neamati</i>	161

14	An In Vitro Screening to Identify Drug-Resistant Mutations for Target-Directed Chemotherapeutic Agents . . . . .	175
	<i>Mohammad Azam</i>	
15	Utilizing AntagomiR (Antisense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells . . . . .	185
	<i>Chinavenmeni S. Velu and H. Leighton Grimes</i>	
16	Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs, and Other Therapeutics to Target Cells . . . . .	197
	<i>Peixuan Guo, Yi Shu, Daniel Binzel, and Mathieu Cinier</i>	
17	Mouse Models for Tumor Metastasis . . . . .	221
	<i>Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang</i>	
	<i>Index</i> . . . . .	229



<http://www.springer.com/978-1-62703-007-6>

Rational Drug Design

Methods and Protocols

Zheng, Y. (Ed.)

2012, XI, 230 p. 58 illus., 22 illus. in color., Hardcover

ISBN: 978-1-62703-007-6

A product of Humana Press